"Ipamorelin is a synthetic pentapeptide that has garnered attention as a highly selective agonist of the ghrelin receptor (GHSR‑1a), also known as the growth hormone secretagogue receptor. Research indicates that this compound functions by mimicking ghrelin's actions at the receptor level, but it may stimulate growth hormone release without substantially supporting other hormonal axes, such as cortisol or prolactin, offering a unique investigative profile in preclinical and early experimental research models."
"Ipamorelin is composed of five amino acid residues: Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂. It belongs to the class of growth hormone-releasing peptides (GHRPs) but distinguishes itself through a precise receptor binding profile. Cryo‑electron microscopy studies indicate that Ipamorelin may bind to a specific pocket within GHSR‑1a. Multiple hydrogen bonds and hydrophobic interactions between its side chains-including D‑2‑Nal and D‑Phe residues-and the receptor may stabilize the complex, inducing conformational changes critical for receptor activation."
"Upon receptor engagement, G-protein coupling initiates intracellular cascades, most notably the activation of adenylate cyclase, which results in increased cyclic AMP levels and the subsequent activation of protein kinase A. Additionally, intracellular calcium modulation may play a role in signaling. These pathways are believed to culminate in the selective release of growth hormone without triggering associated elevations in ACTH, cortisol, prolactin, LH, FSH, or TSH."
Ipamorelin is a synthetic pentapeptide GHSR‑1a agonist composed of Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂ that binds a specific pocket in the ghrelin receptor. Binding involves multiple hydrogen bonds and hydrophobic contacts between D‑2‑Nal and D‑Phe side chains and receptor residues, stabilizing conformations that enable G‑protein coupling. Downstream signaling includes adenylate cyclase activation, raised cAMP, protein kinase A engagement, and potential intracellular calcium modulation. Experimental data indicate primarily selective stimulation of growth hormone release without substantial increases in ACTH, cortisol, prolactin, LH, FSH, or TSH. Ipamorelin’s receptor specificity supports focused preclinical investigation and exploration of therapeutic and safety profiles.
Read at stupidDOPE | Est. 2008
Unable to calculate read time
Collection
[
|
...
]